Piramal Pharma Ltd

NSE: PPLPHARMA · BSE: 543635 · Pharmaceuticals & Biotechnology · 32 announcements

Share price: ₹203.01
Market cap: ₹27,028 Cr
Revenue (annual): ₹8,869 Cr
Net profit (annual): ₹-325.9 Cr
P/E (TTM): -86.2×Sector 47.3×
Promoter holding: 34.80%-0.06% QoQ
FII holding: 12.51%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Business Update 7 Other Announcement 5 Financial Results 3 Share Pledge 2 Results Update 2 Regulatory Approval 2 Merger & Restructuring 2 Employee Stock Options 2 Annual General Meeting 2 Management Change 1 Earnings Call 1 Board Meeting Date 1 Adverse Business Impact 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

31 announcements with these filters

13 Apr 2026 10:20 IST BSE

Regulatory ApprovalAlfa Alert

Piramal Pharma Regulatory Approval

Piramal Pharma Limited successfully closed its US FDA inspection at its Lexington, USA manufacturing facility. The US FDA issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification. This marks the formal and successful conclusion of the inspection initiated in December 2025.

Read the filing ↗